Reports

PBM practices lead US consumers to overpay for generics by 20%

Home/Reports | Posted 01/07/2022

Consumers in the US are overpaying for generics medicines by as much as 20%, a University of Southern California study reports [1]. The white paper calls for transparency across the generic prescription drug supply chain and policies to increase competition and stop anti-competitive practices.

Approaches to streamline biosimilar interchangeable programmes

Home/Reports | Posted 03/06/2022

Dr Yow-Ming Wang provided welcoming remarks during the biosimilars webinar hosted by the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) and the U.S. Food and Drug Administration (FDA).

Brazilian market of biosimilars

Home/Reports | Posted 20/05/2022

As the largest country in South America, Brazil is an important market for the pharmaceutical industry, but the biosimilars still represent less than 2% of the total biological drug market in the country [1].

China–EU market expansion for biosimilars

Home/Reports | Posted 16/05/2022

Hao J stated that the prospects for biosimilar sales in China are huge, but there are many companies in the market battling for share, and so they are slowly turning in the direction of sales abroad, including the European Union (EU). However, in entering the EU they must go up against many large and well-established biopharmaceutical companies. She said that ultimately market share will go to the most efficient and economical producers [1].

Challenges for Chinese companies to bring biosimilars (copy biologicals) to EU

Home/Reports | Posted 06/05/2022

A presentation by Dr Jenny Hao, a pharma operating partner with Converge Partners at the Festival of Biologics meeting in Basel, Switzerland in November 2021, highlights the interest Chinese biosimilars producers have in Europe and the challenges they face.

Pathways for Chinese pharmaceutical companies to enter EU markets

Home/Reports | Posted 29/04/2022

China was significantly behind the European Union (EU) in starting to approve biosimilars/copy biologicals. However, despite the small number of copy biologicals approved in the country, China has been much faster to commercialize such products [1].

Chinese biosimilars (copy biological) in European markets

Home/Reports | Posted 22/04/2022

A presentation entitled ‘International commercialization on biosimilars’ delivered by Dr Jenny Hao of Convergence in November 2021 at the Festival of Biologics meeting in Basel, Switzerland discussed the challenges and opportunities for Chinese biosimilar (copy biological) companies to market their products in the European Union.